EN / 中文
您的位置： 首页 > 2023年2月 第54卷 第2期 > 文字全文
2023年7月 第38卷 第7期11
目录

m6A甲基化修饰在肿瘤免疫中的作用及干预策略

The roles of m6A methylation in tumor immunity and targeted therapy strategies

来源期刊： 广州医药 | 1-8 发布时间：2023-02-27 收稿时间：2025/11/13 18:38:08 阅读量：31
作者：
彭彦茜,
易诚,
陶丽君,
王红胜,
关键词：
m6A甲基化肿瘤免疫肿瘤微环境靶向治疗
m6A methylationtumor immunitytumor microenvironmenttargeted therapy
DOI：
10.3969/j.issn.1000-8535.2023.02.001
收稿时间：
2022-12-12 
修订日期：
 
接收日期：
 
引用总数：
0  
N6-甲基腺苷(N6-methyladenosine, m6A)修饰是真核生物信使 RNA中最丰富的表观遗传修饰,其失调会导致mRNA异常生物学行为如翻译和降解紊乱,从而调控肿瘤发生发展。近期研究表明m6A在免疫调控过程中可发挥重要作用,其不仅可调节免疫细胞的活化,还在肿瘤微环境中免疫应答发挥重要调控作用,从而影响免疫治疗效果。越来越多的证据表明m6A修饰可能是肿瘤免疫治疗的重要潜在干预靶点。本文阐述了免疫细胞中m6A修饰调控及其在肿瘤免疫微环境中相关调节作用,并进一步探讨了靶向m6A调控蛋白在肿瘤免疫治疗中的干预策略及潜在治疗价值。
N6-methyladenosine (m6A) modification is the most abundant epigenetic modification in eukaryotic messenger RNA (messenger RNA). Its dysregulation drives abnormal transcription and translation processes, which promotes the occurrence and development of tumors. Studies have shown that m6A modification can regulate the activation of immune cells and their infiltration into the tumor microenvironment (TME), which may affect the efficiency of immunotherapy. Therefore, m6A modification may be a potential target for tumor immunotherapy. This paper describes the modification of m6A in immune cells and the antitumor immune response associated with TME, and explores the potential therapeutic value of targeting m6A regulators in tumor immunotherapy.
1、 ROUNDTREE I A,EVANS M E,PAN T,et al. Dynamic RNA modifications in gene expression regulation[J]. Cell,2017,169(7):1187-1200. ROUNDTREE I A,EVANS M E,PAN T,et al. Dynamic RNA modifications in gene expression regulation[J]. Cell,2017,169(7):1187-1200.
2、 ZHAO B S,ROUNDTREE I A,HE C.Post-transcriptional gene regulation by mRNA modifications[J]. Nat Rev Mol Cell Biol, 2017,18(1):31-42. ZHAO B S,ROUNDTREE I A,HE C.Post-transcriptional gene regulation by mRNA modifications[J]. Nat Rev Mol Cell Biol, 2017,18(1):31-42.
3、 FU Y,DOMINISSINI D,RECHAVI G,et al. Gene expression regulation mediated through reversible m6A RNA methylation[J]. Nat Rev Genet,2014,15(5):293-306. FU Y,DOMINISSINI D,RECHAVI G,et al. Gene expression regulation mediated through reversible m6A RNA methylation[J]. Nat Rev Genet,2014,15(5):293-306.
4、 LIU J,YUE Y, HAN D, et al. A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation[J]. Nat Chem Biol, 2014,10(2):93-95. LIU J,YUE Y, HAN D, et al. A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation[J]. Nat Chem Biol, 2014,10(2):93-95.
5、 JIA G, FU Y, ZHAO X, et al. N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO[J]. Nat Chem Biol,2011,7(12):885-887. JIA G, FU Y, ZHAO X, et al. N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO[J]. Nat Chem Biol,2011,7(12):885-887.
6、 ZHENG G,DAHL J A,NIU Y,et al. ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility[J]. Mol Cell,2013,49(1):18-29. ZHENG G,DAHL J A,NIU Y,et al. ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility[J]. Mol Cell,2013,49(1):18-29.
7、 WANG X,LU Z,GOMEZ A,et al. N6-methyladenosine-dependent regulation of messenger RNA stability[J]. Nature, 2014,505(7481):117-120. WANG X,LU Z,GOMEZ A,et al. N6-methyladenosine-dependent regulation of messenger RNA stability[J]. Nature, 2014,505(7481):117-120.
8、 WANG X,ZHAO B S,ROUNDTREE I A,et al. N6-methyladenosine Modulates Messenger RNA Translation Efficiency[J]. Cell,2015,161(6):1388-1399. WANG X,ZHAO B S,ROUNDTREE I A,et al. N6-methyladenosine Modulates Messenger RNA Translation Efficiency[J]. Cell,2015,161(6):1388-1399.
9、 TAKABA H, TAKAYANAGI H.The mechanisms of T cell selection in the thymus[J]. Trends Immunol,2017,38(11):805-816. TAKABA H, TAKAYANAGI H.The mechanisms of T cell selection in the thymus[J]. Trends Immunol,2017,38(11):805-816.
10、 LI H B,TONG J,ZHU S,et al. m6A mRNA methylation controls T cell homeostasis by targeting the IL-7/STAT5/SOCS pathways[J]. Nature,2017,548(7667):338-342. LI H B,TONG J,ZHU S,et al. m6A mRNA methylation controls T cell homeostasis by targeting the IL-7/STAT5/SOCS pathways[J]. Nature,2017,548(7667):338-342.
11、 CROTTY S.T Follicular helper cell biology: A decade of discovery and diseases[J]. Immunity,2019,50(5):1132-1148. CROTTY S.T Follicular helper cell biology: A decade of discovery and diseases[J]. Immunity,2019,50(5):1132-1148.
12、 YAO Y,YANG Y,GUO W,et al. METTL3-dependent m6A modification programs T follicular helper cell differentiation[J]. Nat Commun,2021,12(1):1333. YAO Y,YANG Y,GUO W,et al. METTL3-dependent m6A modification programs T follicular helper cell differentiation[J]. Nat Commun,2021,12(1):1333.
13、 TONG J,CAO G,ZHANG T,et al. m6A mRNA methylation sustains Treg suppressive functions[J]. Cell Res,2018,28(2):253-256. TONG J,CAO G,ZHANG T,et al. m6A mRNA methylation sustains Treg suppressive functions[J]. Cell Res,2018,28(2):253-256.
14、 LIU Z,WANG T,SHE Y,et al. N6-methyladenosine-modified circIGF2BP3 inhibits CD8+ T-cell responses to facilitate tumor immune evasion by promoting the deubiquitination of PD-L1 in non-small cell lung cancer[J]. Mol Cancer,2021,20(1):105. LIU Z,WANG T,SHE Y,et al. N6-methyladenosine-modified circIGF2BP3 inhibits CD8+ T-cell responses to facilitate tumor immune evasion by promoting the deubiquitination of PD-L1 in non-small cell lung cancer[J]. Mol Cancer,2021,20(1):105.
15、 DONG L,CHEN C,ZHANG Y,et al. The loss of RNA N6-adenosine methyltransferase Mettl14 in tumor-associated macrophages promotes CD8+ T cell dysfunction and tumor growth[J]. Cancer Cell,2021,39(7):945-957. DONG L,CHEN C,ZHANG Y,et al. The loss of RNA N6-adenosine methyltransferase Mettl14 in tumor-associated macrophages promotes CD8+ T cell dysfunction and tumor growth[J]. Cancer Cell,2021,39(7):945-957.
16、 LU T X, ZHENG Z, ZHANG L, et al. A new model of spontaneous colitis in mice induced by deletion of an RNA m6A methyltransferase component METTL14 in T cells[J]. Cell Mol Gastroenterol Hepatol,2020,10(4):747-761. LU T X, ZHENG Z, ZHANG L, et al. A new model of spontaneous colitis in mice induced by deletion of an RNA m6A methyltransferase component METTL14 in T cells[J]. Cell Mol Gastroenterol Hepatol,2020,10(4):747-761.
17、 ZHOU J,ZHANG X,HU J,et al. m6A demethylase ALKBH5 controls CD4+ T cell pathogenicity and promotes autoimmunity[J]. Sci Adv,2021,7(25):eabg0470. ZHOU J,ZHANG X,HU J,et al. m6A demethylase ALKBH5 controls CD4+ T cell pathogenicity and promotes autoimmunity[J]. Sci Adv,2021,7(25):eabg0470.
18、 DING C, XU H, YU Z, et al. RNA m6A demethylase ALKBH5 regulates the development of γδ T cells[J]. Proc Natl Acad Sci U S A, 2022,119(33):e2203318119. DING C, XU H, YU Z, et al. RNA m6A demethylase ALKBH5 regulates the development of γδ T cells[J]. Proc Natl Acad Sci U S A, 2022,119(33):e2203318119.
19、 HUANG H,ZHANG G,RUAN G X,et al. Mettl14-Mediated m6A modification is essential for germinal center B cell response[J]. J Immunol, 2022,208(8):1924-1936. HUANG H,ZHANG G,RUAN G X,et al. Mettl14-Mediated m6A modification is essential for germinal center B cell response[J]. J Immunol, 2022,208(8):1924-1936.
20、 ZHENG Z, ZHANG L, CUI X L, et al. Control of early B cell development by the RNA N6-Methyladenosine methylation[J]. Cell Rep,2020,31(13):107819. ZHENG Z, ZHANG L, CUI X L, et al. Control of early B cell development by the RNA N6-Methyladenosine methylation[J]. Cell Rep,2020,31(13):107819.
21、 KANG X, CHEN S, PAN L, et al. Deletion of mettl3 at the pro-B stage marginally affects B cell development and profibrogenic activity of B cells in liver fibrosis[J]. J Immunol Res,2022(2022):8118577. KANG X, CHEN S, PAN L, et al. Deletion of mettl3 at the pro-B stage marginally affects B cell development and profibrogenic activity of B cells in liver fibrosis[J]. J Immunol Res,2022(2022):8118577.
22、 NOY R,POLLARD J W.Tumor-associated macrophages: from mechanisms to therapy[J]. Immunity,2014,41(1):49-61. NOY R,POLLARD J W.Tumor-associated macrophages: from mechanisms to therapy[J]. Immunity,2014,41(1):49-61.
23、 TONG J,WANG X,LIU Y,et al. Pooled CRISPR screening identifies m6A as a positive regulator of macrophage activation[J]. Sci Adv,2021,7(18):eabd4742. TONG J,WANG X,LIU Y,et al. Pooled CRISPR screening identifies m6A as a positive regulator of macrophage activation[J]. Sci Adv,2021,7(18):eabd4742.
24、 WANG X,JI Y,FENG P,et al. The m6A reader IGF2BP2 regulates macrophage phenotypic activation and inflammatory diseases by stabilizing TSC1 and PPARγ[J]. Adv Sci (Weinh),2021,8(13):2100209. WANG X,JI Y,FENG P,et al. The m6A reader IGF2BP2 regulates macrophage phenotypic activation and inflammatory diseases by stabilizing TSC1 and PPARγ[J]. Adv Sci (Weinh),2021,8(13):2100209.
25、 GUO M,YAN R,JI Q,et al. IFN regulatory Factor-1 induced macrophage pyroptosis by modulating m6A modification of circ_0029589 in patients with acute coronary syndrome[J]. Int Immunopharmacol,2020(86):106800. GUO M,YAN R,JI Q,et al. IFN regulatory Factor-1 induced macrophage pyroptosis by modulating m6A modification of circ_0029589 in patients with acute coronary syndrome[J]. Int Immunopharmacol,2020(86):106800.
26、 SUN Z, CHEN W, WANG Z, et al. Matr3 reshapes m6A modification complex to alleviate macrophage inflammation during atherosclerosis[J]. Clin Immunol,2022(245):109176. SUN Z, CHEN W, WANG Z, et al. Matr3 reshapes m6A modification complex to alleviate macrophage inflammation during atherosclerosis[J]. Clin Immunol,2022(245):109176.
27、 ZHOU K, CHENG T, ZHAN J, et al. Targeting tumor-associated macrophages in the tumor microenvironment[J]. Oncol Lett,2020,20(5):234. ZHOU K, CHENG T, ZHAN J, et al. Targeting tumor-associated macrophages in the tumor microenvironment[J]. Oncol Lett,2020,20(5):234.
28、 LIU Y,LIU Z,TANG H,et al. The N6-methyladenosine (m6A)-forming enzyme METTL3 facilitates M1 macrophage polarization through the methylation of STAT1 mRNA[J]. Am J Physiol Cell Physiol, 2019,317(4):C762-C775. LIU Y,LIU Z,TANG H,et al. The N6-methyladenosine (m6A)-forming enzyme METTL3 facilitates M1 macrophage polarization through the methylation of STAT1 mRNA[J]. Am J Physiol Cell Physiol, 2019,317(4):C762-C775.
29、 YIN H,ZHANG X,YANG P,et al. RNA m6A methylation orchestrates cancer growth and metastasis via macrophage reprogramming[J]. Nat Commun,2021,12(1):1394. YIN H,ZHANG X,YANG P,et al. RNA m6A methylation orchestrates cancer growth and metastasis via macrophage reprogramming[J]. Nat Commun,2021,12(1):1394.
30、 SHI B,LIU W W,YANG K,et al. The role, mechanism, and application of RNA methyltransferase METTL14 in gastrointestinal cancer[J]. Mol Cancer,2022,21(1):163. SHI B,LIU W W,YANG K,et al. The role, mechanism, and application of RNA methyltransferase METTL14 in gastrointestinal cancer[J]. Mol Cancer,2022,21(1):163.
31、 LIU Y,SHI M,HE X,et al. LncRNA-PACERR induces pro-tumour macrophages via interacting with miR-671-3p and m6A-reader IGF2BP2 in pancreatic ductal adenocarcinoma[J]. J Hematol Oncol, 2022,15(1):52. LIU Y,SHI M,HE X,et al. LncRNA-PACERR induces pro-tumour macrophages via interacting with miR-671-3p and m6A-reader IGF2BP2 in pancreatic ductal adenocarcinoma[J]. J Hematol Oncol, 2022,15(1):52.
32、 MORVAN M G, LANIER L L.NK cells and cancer: you can teach innate cells new tricks[J]. Nat Rev Cancer,2016,16(1):7-19. MORVAN M G, LANIER L L.NK cells and cancer: you can teach innate cells new tricks[J]. Nat Rev Cancer,2016,16(1):7-19.
33、 SPITS H, BERNINK J H, LANIER L. NK cells and type 1 innate lymphoid cells: partners in host defense[J]. Nat Immunol,2016,17(7):758-764. SPITS H, BERNINK J H, LANIER L. NK cells and type 1 innate lymphoid cells: partners in host defense[J]. Nat Immunol,2016,17(7):758-764.
34、 MA S,YAN J,BARR T, et al. The RNA m6A reader YTHDF2 controls NK cell antitumor and antiviral immunity[J]. J Exp Med,2021,218(8):e20210279. MA S,YAN J,BARR T, et al. The RNA m6A reader YTHDF2 controls NK cell antitumor and antiviral immunity[J]. J Exp Med,2021,218(8):e20210279.
35、 SONG H,SONG J,CHENG M,et al. METTL3-mediated m6A RNA methylation promotes the anti-tumour immunity of natural killer cells[J]. Nat Commun,2021,12(1):5522. SONG H,SONG J,CHENG M,et al. METTL3-mediated m6A RNA methylation promotes the anti-tumour immunity of natural killer cells[J]. Nat Commun,2021,12(1):5522.
36、 STEINMAN R M,BANCHEREAU J.Taking dendritic cells into medicine[J]. Nature,2007,449(7161):419-426. STEINMAN R M,BANCHEREAU J.Taking dendritic cells into medicine[J]. Nature,2007,449(7161):419-426.
37、 WANG H,HU X,HUANG M,et al. Mettl3-mediated mRNA m6A methylation promotes dendritic cell activation[J]. Nat Commun,2019,10(1):1898. WANG H,HU X,HUANG M,et al. Mettl3-mediated mRNA m6A methylation promotes dendritic cell activation[J]. Nat Commun,2019,10(1):1898.
38、 WU H, XU Z, WANG Z,et al. Dendritic cells with METTL3 gene knockdown exhibit immature properties and prolong allograft survival[J]. Genes Immun,2020,21(3):193-202. WU H, XU Z, WANG Z,et al. Dendritic cells with METTL3 gene knockdown exhibit immature properties and prolong allograft survival[J]. Genes Immun,2020,21(3):193-202.
39、 HAN D,LIU J,CHEN C,et al. Anti-tumour immunity controlled through mRNA m6A methylation and YTHDF1 in dendritic cells[J]. Nature,2019,566(7743):270-274. HAN D,LIU J,CHEN C,et al. Anti-tumour immunity controlled through mRNA m6A methylation and YTHDF1 in dendritic cells[J]. Nature,2019,566(7743):270-274.
40、 BINNEWIES M, ROBERTS E W, KERSTEN K, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy[J]. Nat Med,2018,24(5):541-550. BINNEWIES M, ROBERTS E W, KERSTEN K, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy[J]. Nat Med,2018,24(5):541-550.
41、 TANG H,QIAO J,FU Y X.Immunotherapy and tumor microenvironment[J]. Cancer Lett, 2016, 370(1):85-90. TANG H,QIAO J,FU Y X.Immunotherapy and tumor microenvironment[J]. Cancer Lett, 2016, 370(1):85-90.
42、 LU M, ZHANG Z, XUE M, et al. N6-methyladenosine modification enables viral RNA to escape recognition by RNA sensor RIG-I[J]. Nat Microbiol,2020,5(4):584-598. LU M, ZHANG Z, XUE M, et al. N6-methyladenosine modification enables viral RNA to escape recognition by RNA sensor RIG-I[J]. Nat Microbiol,2020,5(4):584-598.
43、 SHULMAN Z,STERN-GINOSSAR N.The RNA modification N6-methyladenosine as a novel regulator of the immune system[J]. Nat Immunol,2020,21(5):501-512. SHULMAN Z,STERN-GINOSSAR N.The RNA modification N6-methyladenosine as a novel regulator of the immune system[J]. Nat Immunol,2020,21(5):501-512.
44、 TSIAMBAS E,CHRYSOVERGIS A,PAPANIKOLAOU V, et al. Impact of Ribosome Activity on SARS-CoV-2 LNP-Based mRNA Vaccines[J]. Front Mol Biosci,2021(8):654866. TSIAMBAS E,CHRYSOVERGIS A,PAPANIKOLAOU V, et al. Impact of Ribosome Activity on SARS-CoV-2 LNP-Based mRNA Vaccines[J]. Front Mol Biosci,2021(8):654866.
45、 LAN H,LIU Y,LIU J,et al. Tumor-associated macrophages promote oxaliplatin resistance via METTL3-mediated m6A of TRAF5 and necroptosis in colorectal cancer[J]. Mol Pharm,2021,18(3):1026-1037. LAN H,LIU Y,LIU J,et al. Tumor-associated macrophages promote oxaliplatin resistance via METTL3-mediated m6A of TRAF5 and necroptosis in colorectal cancer[J]. Mol Pharm,2021,18(3):1026-1037.
46、 SHEN S, YAN J, ZHANG Y,et al. N6-methyladenosine (m6A)-mediated messenger RNA signatures and the tumor immune microenvironment can predict the prognosis of hepatocellular carcinoma[J]. Ann Transl Med,2021,9(1):59. SHEN S, YAN J, ZHANG Y,et al. N6-methyladenosine (m6A)-mediated messenger RNA signatures and the tumor immune microenvironment can predict the prognosis of hepatocellular carcinoma[J]. Ann Transl Med,2021,9(1):59.
47、 LUO Y,SUN Y,LI L,et al. METTL3 may regulate testicular germ cell tumors through EMT and immune pathways[J]. Cell Transplant, 2020(29):963689720946653. LUO Y,SUN Y,LI L,et al. METTL3 may regulate testicular germ cell tumors through EMT and immune pathways[J]. Cell Transplant, 2020(29):963689720946653.
48、 WANG L, HUI H, AGRAWAL K,et al. m6 A RNA methyltransferases METTL3/14 regulate immune responses to anti-PD-1 therapy[J]. EMBO J,2020,39(20):e104514. WANG L, HUI H, AGRAWAL K,et al. m6 A RNA methyltransferases METTL3/14 regulate immune responses to anti-PD-1 therapy[J]. EMBO J,2020,39(20):e104514.
49、 NI H H,ZHANG L,HUANG H,et al. Connecting METTL3 and intratumoural CD33+ MDSCs in predicting clinical outcome in cervical cancer[J]. J Transl Med,2020,18(1):393. NI H H,ZHANG L,HUANG H,et al. Connecting METTL3 and intratumoural CD33+ MDSCs in predicting clinical outcome in cervical cancer[J]. J Transl Med,2020,18(1):393.
50、 HE X, TAN L, NI J, et al. Expression pattern of m6A regulators is significantly correlated with malignancy and antitumor immune response of breast cancer[J]. Cancer Gene Ther,2021,28(3-4):188-196. HE X, TAN L, NI J, et al. Expression pattern of m6A regulators is significantly correlated with malignancy and antitumor immune response of breast cancer[J]. Cancer Gene Ther,2021,28(3-4):188-196.
51、 YI L,WU G,GUO L,et al. Comprehensive analysis of the PD-L1 and immune infiltrates of m6A RNA methylation regulators in head and neck squamous cell carcinoma[J]. Mol Ther Nucleic Acids, 2020(21):299-314. YI L,WU G,GUO L,et al. Comprehensive analysis of the PD-L1 and immune infiltrates of m6A RNA methylation regulators in head and neck squamous cell carcinoma[J]. Mol Ther Nucleic Acids, 2020(21):299-314.
52、 GONG P J,SHAO Y C,YANG Y,et al. Analysis of N6-Methyladenosine methyltransferase reveals METTL14 and ZC3H13 as tumor suppressor genes in breast cancer[J]. Front Oncol,2020(10):578963. GONG P J,SHAO Y C,YANG Y,et al. Analysis of N6-Methyladenosine methyltransferase reveals METTL14 and ZC3H13 as tumor suppressor genes in breast cancer[J]. Front Oncol,2020(10):578963.
53、 LIU Y,LIANG G,XU H,et al. Tumors exploit FTO-mediated regulation of glycolytic metabolism to evade immune surveillance[J]. Cell Metab,2021,33(6):1221-1233.e11. LIU Y,LIANG G,XU H,et al. Tumors exploit FTO-mediated regulation of glycolytic metabolism to evade immune surveillance[J]. Cell Metab,2021,33(6):1221-1233.e11.
54、 YANKOVA E,BLACKABY W,ALBERTELLA M,et al. Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia[J]. Nature,2021,593(7860):597-601. YANKOVA E,BLACKABY W,ALBERTELLA M,et al. Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia[J]. Nature,2021,593(7860):597-601.
55、 CHEN B,YE F,YU L,et al. Development of cell-active N6-methyladenosine RNA demethylase FTO inhibitor[J]. J Am Chem Soc,2012,134(43):17963-17971. CHEN B,YE F,YU L,et al. Development of cell-active N6-methyladenosine RNA demethylase FTO inhibitor[J]. J Am Chem Soc,2012,134(43):17963-17971.
56、 HUANG Y, YAN J, LI Q, et al. Meclofenamic acid selectively inhibits FTO demethylation of m6A over ALKBH5[J]. Nucleic Acids Res,2015,43(1):373-384. HUANG Y, YAN J, LI Q, et al. Meclofenamic acid selectively inhibits FTO demethylation of m6A over ALKBH5[J]. Nucleic Acids Res,2015,43(1):373-384.
57、 WANG R, HAN Z, LIU B, et al. Identification of natural compound radicicol as a potent FTO inhibitor[J]. Mol Pharm,2018,15(9):4092-4098. WANG R, HAN Z, LIU B, et al. Identification of natural compound radicicol as a potent FTO inhibitor[J]. Mol Pharm,2018,15(9):4092-4098.
58、 HE W, ZHOU B, LIU W, et al. Identification of a novel small-molecule binding site of the fat mass and obesity associated protein (FTO)[J]. J Med Chem,2015,58(18):7341-7348. HE W, ZHOU B, LIU W, et al. Identification of a novel small-molecule binding site of the fat mass and obesity associated protein (FTO)[J]. J Med Chem,2015,58(18):7341-7348.
59、 PENG S, XIAO W, JU D, et al. Identification of entacapone as a chemical inhibitor of FTO mediating metabolic regulation through FOXO1[J]. Sci Transl Med,2019,11(488):eaau7116. PENG S, XIAO W, JU D, et al. Identification of entacapone as a chemical inhibitor of FTO mediating metabolic regulation through FOXO1[J]. Sci Transl Med,2019,11(488):eaau7116.
60、 SU R,DONG L,LI C,et al. R-2HG exhibits anti-tumor activity by targeting FTO/m6A/MYC/CEBPA signaling[J]. Cell,2018,172(1-2):90-105.e23. SU R,DONG L,LI C,et al. R-2HG exhibits anti-tumor activity by targeting FTO/m6A/MYC/CEBPA signaling[J]. Cell,2018,172(1-2):90-105.e23.
61、 HUANG Y,SU R,SHENG Y,et al. Small-molecule targeting of oncogenic FTO demethylase in acute myeloid leukemia[J]. Cancer Cell,2019,35(4):677-691.e10. HUANG Y,SU R,SHENG Y,et al. Small-molecule targeting of oncogenic FTO demethylase in acute myeloid leukemia[J]. Cancer Cell,2019,35(4):677-691.e10.
62、 SU R, DONG L, LI Y, et al. Targeting FTO suppresses cancer stem cell maintenance and immune evasion[J]. Cancer Cell,2020,38(1):79-96.e11. SU R, DONG L, LI Y, et al. Targeting FTO suppresses cancer stem cell maintenance and immune evasion[J]. Cancer Cell,2020,38(1):79-96.e11.
63、 HAN X,WANG N,LI J,et al. Identification of nafamostat mesilate as an inhibitor of the fat mass and obesity-associated protein (FTO) demethylase activity[J]. Chem Biol Interact,2019(297):80-84. HAN X,WANG N,LI J,et al. Identification of nafamostat mesilate as an inhibitor of the fat mass and obesity-associated protein (FTO) demethylase activity[J]. Chem Biol Interact,2019(297):80-84.
64、 XIE L J,YANG X T,WANG R L, et al. Identification of flavin mononucleotide as a cell-Active artificial N6 -methyladenosine RNA demethylase[J]. Angew Chem Int Ed Engl,2019,58(15):5028-5032. XIE L J,YANG X T,WANG R L, et al. Identification of flavin mononucleotide as a cell-Active artificial N6 -methyladenosine RNA demethylase[J]. Angew Chem Int Ed Engl,2019,58(15):5028-5032.
65、 KZHYSHKOWSKA J,LARIONOVA I,LIU T.YKL-39 as a potential new target for anti-Angiogenic therapy in cancer[J]. Front Immunol, 2020(10):2930. KZHYSHKOWSKA J,LARIONOVA I,LIU T.YKL-39 as a potential new target for anti-Angiogenic therapy in cancer[J]. Front Immunol, 2020(10):2930.
66、 WANG W,MARINIS J M,BEAL A M,et al. RIP1 kinase drives macrophage-mediated adaptive immune tolerance in pancreatic cancer[J]. Cancer Cell,2018,34(5):757-774.e7. WANG W,MARINIS J M,BEAL A M,et al. RIP1 kinase drives macrophage-mediated adaptive immune tolerance in pancreatic cancer[J]. Cancer Cell,2018,34(5):757-774.e7.
下一篇
作者登录
作者注册
审稿登录
编辑登录
最新资讯

“胶质瘤精准诊疗”专题征稿启事

发布于: 2026-05-29

“精神心理与脑科学：前沿与实践”专题征稿启事

发布于: 2026-05-29

“人工智能与医学融合”专题征稿启事

发布于: 2025-02-19

征稿 |《广州医药》—“医院管理”专栏征稿

发布于: 2025-01-21
学术活动

会议通知|人工智能赋能学科高质量发展专题讲座

发布于: 2025-02-19

广州市第一人民医院烧伤整形美容与创面修复科举办首期EWMA创面管理与修复培训班

发布于: 2026-05-29

提质增效，创新作为，不断提升麻醉服务能力2024工作总结与2025工作计划

发布于: 2025-02-19

2026年广州市医学会血液学分会学术年会暨再生障碍性贫血研讨会圆满落幕

发布于: 2026-06-01
出版者信息






《广州医药》公众号
目录
友情链接
关注微信公众号
首页   | 关于我们   | 联系我们  粤ICP备17084739号-3
关注微信公众号
粤ICP备17084739号-3